Results 1 to 10 of about 5,317,572 (397)
Seminars in Surgical Oncology, 1987 AbstractEven though cisplatin‐based combination chemotherapy results in increased clinical and surgical complete remission rates and improved median survival compared with single‐agent alkylating agent chemotherapy, the 5 year survival rates for stages III and IV ovarian cancer have only improved to 25–30%.
R F, Ozols, R C, Young
+10 more sources
Exosomes promote pre-metastatic niche formation in ovarian cancer [PDF]
Molecular Cancer, 2019 Ovarian cancer is one of the most common gynecological malignancies. Upon initial diagnosis, the majority of patients present with widespread metastatic growth within the peritoneal cavity. This metastatic growth occurs in stages, with the formation of a
Wenlong Feng +4 more
semanticscholar +4 more sources
Epithelial ovarian cancer [PDF]
The Lancet, 2019 Epithelial ovarian cancer generally presents at an advanced stage and is the most common cause of gynaecological cancer death. Treatment requires expert multidisciplinary care. Population-based screening has been ineffective, but new approaches for early diagnosis and prevention that leverage molecular genomics are in development.
S, Lheureux +3 more
openaire +4 more sources
Nature Reviews Disease Primers, 2016 Ovarian cancer is not a single disease and can be subdivided into at least five different histological subtypes that have different identifiable risk factors, cells of origin, molecular compositions, clinical features and treatments. Ovarian cancer is a global problem, is typically diagnosed at a late stage and has no effective screening strategy ...
Matulonis, Ursula A +5 more
+12 more sources
BMJ, 2009 This is the author accepted manuscript. The final version is available from the publisher via the DOI in this record. ; From "Easily Missed": a series of occasional articles highlighting conditions that may be commoner than many doctors realise or may be missed at first presentation.
Hamilton, W, Menon, U
+10 more sources
TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer [PDF]
BioImpacts, 2022 Introduction: Tumor endothelial marker 1 (TEM1) is expressed by tumor vascular endothelial cells in various cancers. Methods: Here, we developed poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) PEGylated with polyethylene glycol (PEG) and ...
Efthymia-Iliana Matthaiou +7 more
doaj +1 more source
BioMed Research International, 2014 Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women, with a few months of abdominal pain and distension. Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surgery ...
Song, Yong Sang +4 more
openaire +5 more sources
British Journal of Cancer, 2001 Abstract Ovarian cancer remains the most lethal gynecologic malignancy in women in the United States. Studies from this year's American Society of Clinical Oncology more clearly defined the role of chemotherapy in women with early stage disease and now suggest that essentially all women with invasive disease should receive chemotherapy ...
Kerbrat, P +12 more
openaire +4 more sources
Scientific Reports, 2022 High-grade serous ovarian cancer (HGSOC) is an aggressive malignancy often diagnosed at an advanced stage. Although most HGSOC patients respond initially to debulking surgery combined with cytotoxic chemotherapy, many ultimately relapse with platinum ...
Adrian Buensuceso +6 more
doaj +1 more source
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
The Journal of the National Comprehensive Cancer Network, 2022 Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis.
D. Armstrong +37 more
semanticscholar +1 more source